心脏术后高清除率危重患儿的阿莫西林-克拉维酸个体化给药建议
该研究基于群体药代动力学分析和靶标 attainment 概率模拟,纳入37例心脏术后接受阿莫西林-克拉维酸(按阿莫西林成分30-60 mg/kg/6 h,输注30分钟)的危重患儿(1日龄至15岁),采集316份阿莫西林和287份克拉维酸血样。阿莫西林采用三室模型、克拉维酸采用二室模型描述,清除率估计值显著增高,但接受血管升压药的患者阿莫西林-克拉维酸清除率降低三分之一。以50%fT>MIC 8 mg/L为药代动力学/药效学靶标,未用血管升压药的患者因阿莫西林清除率增高需要每4小时给药才能达到 adequate 药物暴露;仅在接受血管升压药的患者中,标准每6小时给药方案足以使阿莫西林浓度在给药间隔一半时间内高于MIC。结论认为当前心脏术后危重患儿的阿莫西林-克拉维酸给药方案需要更新,以避免因清除率增高导致的亚治疗浓度和临床失败。
要点
- 心脏术后未用血管升压药的危重患儿阿莫西林清除率显著增高,需每4小时给药以达到50%fT>MIC 8 mg/L的目标。
- 接受血管升压药的患者阿莫西林-克拉维酸清除率降低三分之一,标准每6小时给药方案即可使阿莫西林浓度在给药间隔一半时间内高于MIC。
- 研究纳入37例心脏术后患儿(1日龄至15岁),采集316份阿莫西林和287份克拉维酸血样,阿莫西林用三室模型、克拉维酸用二室模型描述。
- 当前阿莫西林-克拉维酸给药方案(30-60 mg/kg/6 h,输注30分钟)对未用血管升压药的患儿可能导致亚治疗浓度,需更新以避免临床失败。
适用人群与场景
- 危重患儿,年龄1日龄至15岁,接受心脏手术后术后使用阿莫西林-克拉维酸治疗。
处置流程与药物剂量
- 未接受血管升压药的心脏术后危重患儿:阿莫西林-克拉维酸需每4小时给药,以达到50%fT>MIC 8 mg/L的药代动力学/药效学靶标。
- 接受血管升压药的心脏术后危重患儿:标准每6小时给药方案(30-60 mg/kg/6 h,按阿莫西林成分,输注30分钟)足以使阿莫西林浓度在给药间隔一半时间内高于MIC。
研究设计与关键结果
- 研究类型为群体药代动力学分析,纳入37例心脏术后危重患儿(1日龄至15岁),采集316份阿莫西林和287份克拉维酸血样。
- 阿莫西林采用三室模型、克拉维酸采用二室模型描述药代动力学,事先加入异速生长体重标度和成熟度函数以校正体型和年龄。
- 清除率估计值显著增高,但接受血管升压药的患者阿莫西林-克拉维酸清除率降低三分之一。
- 以50%fT>MIC 8 mg/L为靶标,未用血管升压药的患者因阿莫西林清除率增高需要每4小时给药才能达到 adequate 药物暴露;仅在接受血管升压药的患者中,标准每6小时给药方案足以使阿莫西林浓度在给药间隔一半时间内高于MIC。
证据类型、等级与局限
- 证据类型:基于群体药代动力学分析和靶标 attainment 概率模拟的给药建议研究(ClinicalTrials.gov NCT02456974)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心脏术后未接受血管升压药的危重患儿,当前每6小时给药的阿莫西林-克拉维酸方案可能不足,作者建议更新给药方案以避免亚治疗浓度和临床失败。
- 对于心脏术后接受血管升压药的危重患儿,标准每6小时给药方案可维持阿莫西林浓度在给药间隔一半时间内高于MIC。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Children who undergo cardiac surgery are prone to postoperative infections for which amoxicillin-clavulanate is a cornerstone antibiotic. Nevertheless, amoxicillin-clavulanate pharmacokinetics have not been studied in infants and children after cardiac surgery so far. Antibiotic exposure might be highly variable in this population due to the impact of growth, maturation, and specific pathophysiological and surgery-induced alterations. The objective of this study was to develop evidence-based amoxicillin-clavulanate dosing recommendations based on population pharmacokinetic analysis and probability of target attainment simulations in children after cardiac surgery.
METHODS: Critically ill children (aged 1 day to 15 y) who underwent cardiac surgery and who were treated postoperatively with amoxicillin-clavulanate (30-60 mg/kg/6 h based on the amoxicillin component, infused in 30 min) were included. Up to five amoxicillin and clavulanate blood samples were collected per dose at predefined sampling times. Population pharmacokinetics analysis was performed using nonlinear mixed effects modelling software NONMEM.
RESULTS: We collected 316 amoxicillin and 287 clavulanate blood samples from 37 patients. A three-compartment model for amoxicillin and a two-compartment model for clavulanate best described pharmacokinetics, with allometric weight scaling and maturation functions added a priori to scale for size and age. Clearance estimates were remarkably high, except in patients receiving vasopressors, which decreased clearance of amoxicillin-clavulanate by a third. Using a pharmacokinetic/pharmacodynamic target of 50%fT>MIC of 8 mg/L, patients not on vasopressors warranted 4-hourly dosing to achieve adequate drug exposure due to augmented amoxicillin clearance. Only in patients treated with vasopressors was the standard 6-hourly dosing regimen sufficient to attain amoxicillin concentrations above the MIC for half of the dosing interval.
CONCLUSIONS: Current amoxicillin-clavulanate dosing regimens for critically ill children after cardiac surgery need to be updated to avoid subtherapeutic concentrations and clinical failure due to augmented clearance (ClinicalTrials.gov NCT02456974).
参考来源
- Dhont E, Standing JF, Beel E, et al. Individualised amoxicillin-clavulanate dosing recommendations for critically ill children with augmented clearance after cardiac surgery. Int J Antimicrob Agents. 2025. PMID: 40239747. doi:10.1016/j.ijantimicag.2025.107513
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。